



2015-10-20

PRESS RELEASE

## **Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering**

**New York, October 20, 2015 -- Oasmia Pharmaceutical AB has filed an updated registration statement on Form F-1/A with the Securities and Exchange Commission that, due to marketing conditions, will reduce the total amount of the size of its proposed public offering of American Depositary Shares and contemporaneous listing of the American Depositary Shares on the US Nasdaq Capital Market to \$13 million and warrants corresponding to an additional maximum of \$8.1 million. The transaction is expected to price during the week of October 19, subject to customary closing conditions and close three business days thereafter.**

Oasmia will issue to each investor in its proposed offering of American Depositary Shares, or ADSs, one warrant to purchase such ADSs for each two ADSs sold in the offering. The warrants will be exercisable immediately at an exercise price of 125% of the offering price of the ADSs and will expire four (4) years from the date of issuance. At full dilution, the transaction will bring in approximately the same size of Company's initial offering size. The ADSs and warrants will be separately issued, but will be issued and sold in equal proportions.

The Company hereby announces that Joseph Gunnar & Co., LLC, and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC. will act as joint book-running manager(s) for the proposed offering,. The number of American Depositary Shares representing Ordinary Shares to be offered and the price of the American Depositary Shares to be sold in the offering, have not yet been determined.

The offering of these securities will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: info@oasmia.com. In addition, the registration statement, including the prospectus, is available to the public at [www.sec.gov](http://www.sec.gov) or [www.oasmia.com](http://www.oasmia.com).

### **For more information, please contact:**

Julian Aleksov, Executive Chairman,  
Tel: +46 18 50 54 40  
E-mail: [julian.aleksov@oasmia.com](mailto:julian.aleksov@oasmia.com)

Anders Lundin, Chief Financial Officer  
Mobile: +46 70 20 96 300  
E-mail: [anders.lundin@oasmia.com](mailto:anders.lundin@oasmia.com)

Eric Fischgrund  
FischTank Marketing and PR  
E-mail: [eric@fischtankpr.com](mailto:eric@fischtankpr.com)

## **About Oasmia Pharmaceutical AB**

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

---

Information is also available at [www.oasmia.com](http://www.oasmia.com) [www.nasdaqomxnordic.com](http://www.nasdaqomxnordic.com) [www.boerse-frankfurt.de](http://www.boerse-frankfurt.de)  
[twitter.com/oasmia](https://twitter.com/oasmia)

*"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 07.50, CET on October 20, 2015."*